100 related articles for article (PubMed ID: 23896027)
1. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Exp Cell Res; 2013 Nov; 319(18):2812-21. PubMed ID: 23896027
[TBL] [Abstract][Full Text] [Related]
2. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
J Mol Recognit; 2013 Sep; 26(9):432-8. PubMed ID: 23836471
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
J Microsc; 2014 Apr; 254(1):19-30. PubMed ID: 24499016
[TBL] [Abstract][Full Text] [Related]
4. Detecting CD20-rituximab specific interactions on lymphoma cells using atomic force microscopy.
Li M; Liu L; Xi N; Wang Y; Dong Z; Li G; Xiao X; Zhang W
Sci China Life Sci; 2010 Oct; 53(10):1189-95. PubMed ID: 20953941
[TBL] [Abstract][Full Text] [Related]
5. Rapid recognition and functional analysis of membrane proteins on human cancer cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y
J Immunol Methods; 2016 Sep; 436():41-9. PubMed ID: 27374866
[TBL] [Abstract][Full Text] [Related]
6. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy.
Li M; Xiao X; Liu L; Xi N; Wang Y; Dong Z; Zhang W
Scanning; 2013; 35(1):40-6. PubMed ID: 22890585
[TBL] [Abstract][Full Text] [Related]
7. AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells.
Li M; Xiao X; Zhang W; Liu L; Xi N; Wang Y
Cell Immunol; 2014 Aug; 290(2):233-44. PubMed ID: 25117605
[TBL] [Abstract][Full Text] [Related]
8. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
9. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
11. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
13. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
14. TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20.
Kawabata KC; Ehata S; Komuro A; Takeuchi K; Miyazono K
Oncogene; 2013 Apr; 32(16):2096-106. PubMed ID: 22665052
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
16. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
17. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
18. CD20 as a target for therapeutic type I and II monoclonal antibodies.
Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ
Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657
[TBL] [Abstract][Full Text] [Related]
19. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
20. CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.
Pijuan L; Vicioso L; Bellosillo B; Ferrer MD; Baró T; Pedro C; Lloreta-Trull J; Munné A; Serrano S
Am J Surg Pathol; 2005 Oct; 29(10):1399-403. PubMed ID: 16160485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]